5.26
4.36%
-0.24
After Hours:
5.26
Orasure Technologies Inc. stock is currently priced at $5.26, with a 24-hour trading volume of 740.00K.
It has seen a -4.36% decreased in the last 24 hours and a -15.43% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $5.48 pivot point. If it approaches the $5.33 support level, significant changes may occur.
Previous Close:
$5.50
Open:
$5.42
24h Volume:
740.00K
Market Cap:
$402.44M
Revenue:
$405.47M
Net Income/Loss:
$53.66M
P/E Ratio:
9.069
EPS:
0.58
Net Cash Flow:
$131.28M
1W Performance:
+0.19%
1M Performance:
-15.43%
6M Performance:
-2.95%
1Y Performance:
-20.42%
Orasure Technologies Inc. Stock (OSUR) Company Profile
Name
Orasure Technologies Inc.
Sector
Industry
Phone
610-882-1820
Address
220 East First Street, Bethlehem, PA
Orasure Technologies Inc. Stock (OSUR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-03-23 | Resumed | Evercore ISI | In-line |
Sep-22-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
Aug-21-20 | Initiated | Evercore ISI | Outperform |
Aug-10-20 | Initiated | Citigroup | Buy |
Aug-10-20 | Initiated | JP Morgan | Neutral |
Aug-07-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jun-25-20 | Initiated | Lake Street | Buy |
Apr-21-20 | Resumed | Stephens | Equal-Weight |
Oct-23-18 | Resumed | Raymond James | Mkt Perform |
Jul-16-18 | Downgrade | Stephens | Overweight → Equal-Weight |
Nov-02-17 | Downgrade | Jefferies | Buy → Hold |
Feb-09-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jun-13-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-05-15 | Reiterated | Mizuho | Buy |
May-07-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Jan-23-15 | Reiterated | Mizuho | Buy |
Jun-12-14 | Reiterated | Canaccord Genuity | Buy |
Jun-11-14 | Reiterated | Mizuho | Buy |
Dec-21-12 | Initiated | Mizuho | Buy |
Aug-08-12 | Upgrade | Barrington Research | Mkt Perform → Outperform |
Jul-05-12 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Mar-27-12 | Initiated | JMP Securities | Mkt Outperform |
View All
Orasure Technologies Inc. Stock (OSUR) Latest News
OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th
GlobeNewswire Inc.
Insulet (PODD) Surpasses Q4 Earnings and Revenue Estimates
Zacks Investment Research
Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates
Zacks Investment Research
Abbott (ABT) Q4 Earnings Match Estimates
Zacks Investment Research
Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron
Zacks Investment Research
Buy These 4 Low-Beta Stocks to Counter Market Volatility
Zacks Investment Research
Orasure Technologies Inc. Stock (OSUR) Financials Data
Orasure Technologies Inc. (OSUR) Revenue 2024
OSUR reported a revenue (TTM) of $405.47 million for the quarter ending December 31, 2023, a +4.64% rise year-over-year.
Orasure Technologies Inc. (OSUR) Net Income 2024
OSUR net income (TTM) was $53.66 million for the quarter ending December 31, 2023, a +413.17% increase year-over-year.
Orasure Technologies Inc. (OSUR) Cash Flow 2024
OSUR recorded a free cash flow (TTM) of $131.28 million for the quarter ending December 31, 2023, a +218.15% increase year-over-year.
Orasure Technologies Inc. (OSUR) Earnings per Share 2024
OSUR earnings per share (TTM) was $0.72 for the quarter ending December 31, 2023, a +388.00% growth year-over-year.
About Orasure Technologies Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, OMNIgene DISCOVER, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, GenoFIND, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, retail pharmacies, mass merchandisers, and consumers. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.
Cap:
|
Volume (24h):